| Placebo | Treatment | Total | ||||||
---|---|---|---|---|---|---|---|---|---|
Factor | Frequency | % | Mean | Frequency | % | Mean | Frequency | % | Mean |
Gestacional Age at | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Randomization | Â | Â | Â | Â | Â | Â | Â | Â | Â |
< 12w | 9 | 3.0% | 11w.2d | 4 | 1.3% | 11w.4d | 13 | 2.1% | 11w.2d |
(12w-16w) | 103 | 34.1% | 14w.2d | 115 | 37.5% | 14w.3d | 218 | 35.8% | 14w.2d |
(16w-20w) | 190 | 62.8% | 18w.6d | 186 | 61.2% | 18w.3d | 376 | 61.70% | 18w.5d |
>20w* | 2 | 0.7% | 21w.3d | 0 | 0.0% | - | 2 | 0.3% | 21w.3d |
Total | 304 | 100.0% | 17w.1d | 305 | 100.0% | 16w.6d | 609 | 100.0% | 16w.7d |
Nugent Score | Â | Â | Â | Â | Â | Â | Â | Â | Â |
<4 | 2 | 0.7% | 2.5 | 1 | 0.3% | 1.0 | 3 | 0.5% | 2.0 |
4-6 | 81 | 26.6% | 5.4 | 90 | 29.5% | 5.4 | 171 | 28.1% | 5.4 |
7-8 | 181 | 59.5% | 7.6 | 173 | 56.7% | 7.6 | 354 | 58.5% | 7.6 |
9-10 | 40 | 13.2% | 9.2 | 41 | 13.4% | 9.4 | 81 | 13.3% | 9.3 |
Total | 304 | 100.0% | 7.2 | 305 | 100.0% | 7.2 | 609 | 100.0% | 7.2 |
Lag between elegible | Â | Â | Â | Â | Â | Â | Â | Â | |
Nugent score and | Â | Â | Â | Â | Â | Â | Â | Â | Â |
randomization | Â | Â | Â | Â | Â | Â | Â | Â | Â |
< = 2 weeks | 180 | 59.2% | 1w.3d | 184 | 60.3% | 1w.1d | 364 | 59.8% | 1w.2d |
>2 weeks | 124 | 40.8% | 3w.1d | 121 | 39.7% | 3w.3d | 245 | 40.2% | 3w.2d |
Total | 304 | 100.0% | 2w.1d | 305 | 100.0% | 2w.0d | 609 | 100.0% | 2w.0d |
pH | Â | Â | Â | Â | Â | Â | Â | Â | Â |
4.5 | 90 | 29.6% | 4.50 | 81 | 26.6% | 4.50 | 171 | 28.1% | 4.50 |
5.0 | 151 | 49.7% | 5.00 | 156 | 51.1% | 5.00 | 307 | 50.4% | 5.00 |
5.5 or 6.0 | 63 | 20.7% | 5.52 | 68 | 22.3% | 5.54 | 131 | 21.5% | 5.53 |
Total | 304 | 100.0% | 4.96 | 305 | 100.0% | 4.99 | 609 | 100.0% | 4.97 |
Age (years) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
<18 | 41 | 13.5% | 16.4 | 39 | 12.8% | 16.4 | 80 | 13.1% | 16.4 |
> = 18 | 263 | 86.5% | 24.8 | 266 | 87.2% | 24.6 | 529 | 86.9% | 24.7 |
Total | 304 | 100.0% | 23.7 | 305 | 100.0% | 23.6 | 609 | 100.0% | 23.6 |
Height (m) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
< = 1.55 | 83 | 27.3% | 1.52 | 72 | 23.6% | 1.52 | 155 | 25.5% | 1.52 |
>1.55 | 221 | 72.7% | 1.63 | 233 | 76.4%1 | 1.63 | 454 | 74.5% | 1.63 |
Total | 304 | 100.0% | 1.60 | 305 | 100.0% | 1.60 | 609 | 100.0% | 1.60 |
Ethnicity | Â | Â | Â | Â | Â | Â | Â | Â | Â |
White | 105 | 34.5% | Â | 103 | 33.8% | Â | 208 | 34.2% | Â |
Black | 199 | 65.5% | Â | 200 | 65.6% | Â | 399 | 65.5% | Â |
NA | 0 | 0% | Â | 2 | 0.7% | Â | 2 | 0.3% | Â |
Total | 304 | 100.0% | Â | 305 | 100.0% | Â | 609 | 100.0% | Â |
Nulliparity | Â | Â | Â | Â | Â | Â | Â | Â | Â |
No | 109 | 35.9% | Â | 115 | 37.7% | Â | 224 | 36.8% | Â |
Yes | 195 | 64.1% | Â | 190 | 62.3% | Â | 385 | 63.2% | Â |
Total | 304 | 100.0% | Â | 305 | 100.0% | Â | 609 | 100.0% | Â |
Adherence | Â | Â | Â | Â | Â | Â | Â | Â | Â |
No | 107 | 35.2% | Â | 104 | 34.1% | Â | 211 | 34.6% | Â |
Yes | 197 | 64.8% | Â | 201 | 65.9% | Â | 398 | 65.4% | Â |
Total | 304 | 100.0% | Â | 305 | 100.0% | Â | 609 | 100.0% | Â |